Warning: Undefined variable $page_cluster_id in /home3/thegood9/public_html/website_70aad9ea/header.php on line 29



Warning: Undefined variable $subreddit_drop in /home3/thegood9/public_html/website_70aad9ea/functions.php on line 998

Tag Directory / BIOTECH     showing 1–1 of 1   RSS

for: Thursday, May 21, 2026



Eli Lilly’s Triple Combo Obesity Drug Tops 28% Weight Loss in a Pivotal Trial

Frank Vinluan / medcitynews - Eli Lilly’s retatrutide set a high mark in weight loss for obesity drugs, but with clinical trial results that show some new side effects. More detailed data from the Phase 3 study are scheduled for presentation next month during the American Diabetes Ass…

AI Summary: Eli Lilly’s triple‑agonist produced average weight loss exceeding 28% in a pivotal study, positioning the drug as a leader among late‑stage obesity candidates. The results close the gap with surgical outcomes and promise major clinical and commercial impact—assuming regulators are satisfied and long‑term safety and durability data hold up.


GLP-1 drugs closing gap with bariatric surgery

Weight loss drug semaglutide helps patients who do not respond to bariatric surgery, research finds

9 days / medicalxpress

Semaglutide versus placebo in individuals with poor weight loss after bariatric surgery: a double-blinded, randomized, placebo-controlled trial

10 days / nature / Chloe Stanley

GLP-1s are closing the gap with bariatric surgery. Here’s what the research shows.

10 days / beckershospitalreview / Ella Jeffries


GLP-1 mechanisms and potential cancer benefits

GLP-1s and cancer outcomes: What new research shows

9 days / beckershospitalreview / Elizabeth Gregerson

Ozempic and other GLP-1 RAs could slow progression of some cancers, data suggest

9 days / medicalxpress

Researchers identify avenue for enhanced GLP-1-induced weight loss

9 days / medicalxpress


Lilly’s retatrutide trial: 28% weight loss and implications

Inside Makary’s ouster; Another win for Lilly’s triple-G; and more

8 days / endpoints / Max Gelman

Eli Lilly’s Triple Combo Obesity Drug Tops 28% Weight Loss in a Pivotal Trial

10 days / medcitynews / Frank Vinluan

Lilly’s triple agonist still leads among late-stage obesity assets

10 days / endpoints / Elizabeth Cairns

Experimental Drug Yields Dramatic Weight Loss

10 days / nytimes / Gina Kolata and Rebecca Robbins


All Other Stories

Telehealth is Making GLP-1s More Accessible – But Access Alone isn’t Enough

13 hrs / medcitynews / Ro Huntriss

ASCO 2026: updates on weight loss drugs and cancer

2 days / cancerresearchuk / Tim Gunn

CVS obesity drug deal puts Lilly on equal footing with Novo

3 days / healthcaredive / Kristin Jensen

Tirzepatide superior to intensified conventional care for early type 2 diabetes

4 days / medicalxpress

Low-insulinemic, planetary health diets optimize weight management during menopause

4 days / medicalxpress

EU regulator approves pill form of Novo Nordisk's Wegovy weight loss drug

9 days / medicalxpress


Back to Top


BIOTECH Heatmap

90 days, weeks are vertical, left is older; hover for info, click to see that day's coverage.


StackHealth RSS

You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Alzheimer's disease, Medicare Advantage (not listed), Corporate Takeover, Medical Devices and look for the RSS link.

Back to Top
↑

NorthFeed Inc. Terms and Conditions / Privacy Policy

Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.